These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 21992076

  • 1. A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification.
    Bucci FA, Waterbury LD.
    Curr Med Res Opin; 2011 Dec; 27(12):2235-9. PubMed ID: 21992076
    [Abstract] [Full Text] [Related]

  • 2. Prostaglandin E2 inhibition of ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification.
    Bucci FA, Waterbury LD.
    Adv Ther; 2011 Dec; 28(12):1089-95. PubMed ID: 22105509
    [Abstract] [Full Text] [Related]

  • 3. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.
    Walters T, Raizman M, Ernest P, Gayton J, Lehmann R.
    J Cataract Refract Surg; 2007 Sep; 33(9):1539-45. PubMed ID: 17720067
    [Abstract] [Full Text] [Related]

  • 4. Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%.
    Heier JS, Awh CC, Busbee BG, Waterbury LD, Daniel P, Stoller GL, Cleary TS.
    Retina; 2009 Oct; 29(9):1310-3. PubMed ID: 19934822
    [Abstract] [Full Text] [Related]

  • 5. Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: aqueous drug absorption and prostaglandin E2 levels.
    Bucci FA, Waterbury LD.
    J Cataract Refract Surg; 2008 Sep; 34(9):1509-12. PubMed ID: 18721711
    [Abstract] [Full Text] [Related]

  • 6. Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (acular LS) and nepafenac 0.1% (nevanac) in patients undergoing phacoemulsification.
    Bucci FA, Waterbury LD, Amico LM.
    Am J Ophthalmol; 2007 Jul; 144(1):146-7. PubMed ID: 17601444
    [Abstract] [Full Text] [Related]

  • 7. Effect of topical ketorolac 0.4%, nepafenac 0.1%, and bromfenac 0.09% on postoperative inflammation using laser flare photometry in patients having phacoemulsification.
    Sahu S, Ram J, Bansal R, Pandav SS, Gupta A.
    J Cataract Refract Surg; 2015 Oct; 41(10):2043-8. PubMed ID: 26703278
    [Abstract] [Full Text] [Related]

  • 8. Re: Pharmacokinetics and pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.
    Bucci FA, Waterbury LD.
    J Cataract Refract Surg; 2008 Aug; 34(8):1226; author reply 1226-7. PubMed ID: 18655957
    [No Abstract] [Full Text] [Related]

  • 9. Nepafenac: an ophthalmic nonsteroidal antiinflammatory drug for pain after cataract surgery.
    Jones BM, Neville MW.
    Ann Pharmacother; 2013 Jun; 47(6):892-6. PubMed ID: 23715071
    [Abstract] [Full Text] [Related]

  • 10. Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing.
    Bucci FA, Waterbury LD.
    Adv Ther; 2009 Jun; 26(6):645-50. PubMed ID: 19568702
    [Abstract] [Full Text] [Related]

  • 11. Concentration and dosing of ketorolac versus bromfenac.
    Gayton J.
    J Cataract Refract Surg; 2009 Jul; 35(7):1319; author reply 1320. PubMed ID: 19545832
    [No Abstract] [Full Text] [Related]

  • 12. Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial.
    Duong HV, Westfield KC, Chalkley TH.
    J Cataract Refract Surg; 2007 Nov; 33(11):1925-9. PubMed ID: 17964399
    [Abstract] [Full Text] [Related]

  • 13. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification.
    Almeida DR, Khan Z, Xing L, Bakar SN, Rahim K, Urton T, El-Defrawy SR.
    J Cataract Refract Surg; 2012 Sep; 38(9):1537-43. PubMed ID: 22795976
    [Abstract] [Full Text] [Related]

  • 14. Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye.
    Chastain JE, Sanders ME, Curtis MA, Chemuturi NV, Gadd ME, Kapin MA, Markwardt KL, Dahlin DC.
    Exp Eye Res; 2016 Apr; 145():58-67. PubMed ID: 26474497
    [Abstract] [Full Text] [Related]

  • 15. Double-masked comparison of ketorolac tromethamine 0.4% versus nepafenac sodium 0.1% for postoperative healing rates and pain control in eyes undergoing surface ablation.
    Trattler W, McDonald M.
    Cornea; 2007 Jul; 26(6):665-9. PubMed ID: 17592313
    [Abstract] [Full Text] [Related]

  • 16. REDUCTION OF VITREOUS PROSTAGLANDIN E2 LEVELS AFTER TOPICAL ADMINISTRATION OF INDOMETHACIN 0.5%, BROMFENAC 0.09%, AND NEPAFENAC 0.1.
    Russo A, Morescalchi F, Vezzoli S, Bernini M, Turano R, Costagliola C, De Ferrari F, Semeraro F.
    Retina; 2016 Jun; 36(6):1227-31. PubMed ID: 26562569
    [Abstract] [Full Text] [Related]

  • 17. VITREOUS PROSTAGLANDIN E2 CHANGES AFTER TOPICAL ADMINISTRATION OF DICLOFENAC 0.1%, INDOMETHACIN 0.5%, NEPAFENAC 0.3%, AND BROMFENAC 0.09.
    Pastore MR, De Giacinto C, Cirigliano G, D'Aloisio R, Addobbati R, Agostinis C, Radillo O, Di Martino G, Di Nicola M, Cecchini P, Tognetto D.
    Retina; 2020 Sep; 40(9):1838-1845. PubMed ID: 31800462
    [Abstract] [Full Text] [Related]

  • 18. Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK).
    Durrie DS, Kennard MG, Boghossian AJ.
    Adv Ther; 2007 Sep; 24(6):1278-85. PubMed ID: 18165210
    [Abstract] [Full Text] [Related]

  • 19. Bromfenac ophthalmic solution 0.09 %: human aqueous humor concentration detected by high-performance liquid chromatography.
    Macrì A, Vagge A, Salis A, Fucile C, Marini V, Martelli A, Giuffrida S, Iester M, Damonte G, Mattioli F.
    Int Ophthalmol; 2017 Apr; 37(2):417-421. PubMed ID: 27324371
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.